hema.to achieves FDA compliance in record time

hema.to achieved FDA compliance as a Class I device less than four months after receiving its CE mark. This was made possible by hema.to’s team and regulatory partners, including QServe Group, Jennifer Hadfield, and Be-on-Quality.

The photo shows Aleks and Jennifer registering the device; the FDA sent the good news the following day.